Mersana Therapeutics (MRSN) Revenue & Revenue Breakdown
Mersana Therapeutics Revenue Highlights
Latest Revenue (Y)
$40.50M
Latest Revenue (Q)
$12.60M
Mersana Therapeutics Revenue by Period
Mersana Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $40.50M | 9.88% |
| 2023-12-31 | $36.85M | 38.65% |
| 2022-12-31 | $26.58M | 61716.28% |
| 2021-12-31 | $43.00K | -94.81% |
| 2020-12-31 | $828.00K | -98.03% |
| 2019-12-31 | $42.12M | 297.61% |
| 2018-12-31 | $10.59M | -39.62% |
| 2017-12-31 | $17.55M | -30.30% |
| 2016-12-31 | $25.17M | 142.99% |
| 2015-12-31 | $10.36M | - |
Mersana Therapeutics generated $40.50M in revenue during NA 2024, up 9.88% compared to the previous quarter, and up 96.14% compared to the same period a year ago.
Mersana Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $12.60M | 449.41% |
| 2024-06-30 | $2.29M | -75.20% |
| 2024-03-31 | $9.24M | -13.61% |
| 2023-12-31 | $10.70M | 39.01% |
| 2023-09-30 | $7.70M | -27.75% |
| 2023-06-30 | $10.65M | 36.55% |
| 2023-03-31 | $7.80M | -46.88% |
| 2022-12-31 | $14.69M | 163.56% |
| 2022-09-30 | $5.57M | 30.09% |
| 2022-06-30 | $4.28M | 110.41% |
| 2022-03-31 | $2.04M | 18409.09% |
| 2021-12-31 | $11.00K | - |
| 2021-09-30 | $11.00K | - |
| 2021-06-30 | $11.00K | - |
| 2021-03-31 | $11.00K | - |
| 2020-12-31 | $11.00K | - |
| 2020-09-30 | $11.00K | -98.62% |
| 2020-06-30 | $796.00K | 7136.36% |
| 2020-03-31 | $11.00K | -73.81% |
| 2019-12-31 | $42.00K | -95.02% |
| 2019-09-30 | $844.00K | 317.82% |
| 2019-06-30 | $202.00K | -99.51% |
| 2019-03-31 | $41.03M | 3354.12% |
| 2018-12-31 | $1.19M | -44.77% |
| 2018-09-30 | $2.15M | -48.68% |
| 2018-06-30 | $4.19M | 36.78% |
| 2018-03-31 | $3.06M | -6.04% |
| 2017-12-31 | $3.26M | -47.97% |
| 2017-09-30 | $6.27M | 68.15% |
| 2017-06-30 | $3.73M | -13.12% |
| 2017-03-31 | $4.29M | -64.24% |
| 2016-12-31 | $12.00M | 267.75% |
| 2016-09-30 | $3.26M | -47.51% |
| 2016-06-30 | $6.21M | 68.11% |
| 2016-03-31 | $3.70M | - |
Mersana Therapeutics generated $12.60M in revenue during Q3 2024, up 449.41% compared to the previous quarter, and up 118.25% compared to the same period a year ago.
Mersana Therapeutics Revenue Breakdown
Mersana Therapeutics Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 |
|---|---|---|
| Performance Obligations | $8.40M | $1.80M |
Mersana Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Performance Obligations (100.00%).
Mersana Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RCUS | Arcus Biosciences | $258.00M | $48.00M |
| DAWN | Day One Biopharmaceuticals | $131.16M | $20.07M |
| AMLX | Amylyx Pharmaceuticals | $87.37M | $416.00K |
| KURA | Kura Oncology | $53.88M | - |
| MRSN | Mersana Therapeutics | $40.50M | $12.60M |
| MRUS | Merus | $36.13M | $11.77M |
| SNDX | Syndax Pharmaceuticals | $23.68M | $12.50M |
| RLAY | Relay Therapeutics | $10.01M | - |
| XFOR | X4 Pharmaceuticals | $2.56M | $560.00K |
| CGEM | Cullinan Oncology | - | - |
| PTGX | Protagonist Therapeutics | - | $4.67M |
| VRDN | Viridian Therapeutics | - | $86.00K |
| RVMD | Revolution Medicines | - | - |
| REPL | Replimune Group | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| HOOK | HOOKIPA Pharma | - | $4.70M |
| PLRX | Pliant Therapeutics | - | - |
MRSN Revenue FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools